La catena delle opzioni mostra i dati chiave delle opzioni azionarie di GH Research a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per GH Research..

GH Research (NASDAQ:GHRS) Azioni, Catena delle Opzioni

GH Research

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.

GH Research PLC

Veru Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERU#NASDAQ">VERU</a>), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from a meta-analysis presentation at ObesityWeek, which took place November 5, 2024, in San Antonio, Texas.
Highlights from the presentation: The objective of the meta-analysis was to determine the effects of enobosarm on body composition in older patients that had obesity who were enrolled in 4 previously conducted randomized clinical trials of enobosarm that measured body composition including Phase 2 older males and postmenopausal women, Phase 2 advanced cancer patients with muscle wasting, and two Phase 3 advanced lung cancer patients with cancer wasting.
Meta-analysis was conducted in older (≥60 years old) subjects with obesity (BMI ≥30), treated with enobosarm 3mg per day versus placebo, and who had a Day 84 (n= 60) and Day 147 (n=45) DEXA scans to assess body composition.
Results of DEXA scan assessments of body composition in older subjects with obesity: At Day 84, enobosarm 3mg treatment compared to placebo resulted in an absolute increase in lean mass (0.05 kg enobosarm vs -1.54 kg placebo) and absolute decrease in fat mass (-1.48 kg enobosarm vs placebo -0.35 kg).
At Day 147, enobosarm 3mg treatment compared to placebo resulted an absolute increase in lean mass (-0.79 kg enobosarm vs -1.77 kg placebo) and absolute decrease in fat mass (-2.05 kg enobosarm vs -0.05 kg placebo).
At Day 147, enobosarm 3mg treated subjects compared to placebo had greater total weight loss by DEXA scan (-2.93 kg for enobosarm and -2.11 kg for placebo).
Enobosarm was generally well-tolerated with no increase in gastrointestinal side effects.

Biotech

News

General

VERU

Veru Announces Meta-analysis Of Body Composition Data From Older Patients With Obesity Which Supports Potential For Enobosarm To Optimize Weight Loss At ObesityWeek

Monness, Crespi, Hardt analyst Gus Gala downgrades Marqeta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) from Buy to Neutral.

Downgrades

Analyst Ratings

Monness, Crespi, Hardt Downgrades Marqeta to Neutral

Barclays analyst Andrew Mok maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and raises the price target from $405 to $420.

Price Target

Barclays Maintains Overweight on Cigna, Raises Price Target to $420

Marathon Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) shares are trading higher after its&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41740316/marathon-petroleum-corp-reports-third-quarter-2024-results" rel="noreferrer noopener">third-quarter results</a>.
Total revenues and other income of&nbsp;$35.4 billion&nbsp;topped the consensus of&nbsp;$32.8 billion.
Adjusted EBITDA was&nbsp;$2.49 billion&nbsp;for the quarter, compared with&nbsp;$5.71 billion in prior year quarter. Refining operating costs per barrel were&nbsp;$5.30&nbsp;versus&nbsp;$5.14&nbsp;a year ago.&nbsp;
Read: <a target="_blank" href="https://www.benzinga.com/news/24/11/41725310/marathon-petroleum-q3-earnings-preview-can-strong-sales-volume-offset-rising-costs" rel="noreferrer noopener">Marathon Petroleum Q3 Earnings Preview: Can Strong Sales Volume Offset Rising Costs?</a>
Refining &amp; Marketing refined product sales volume for the quarter was 3,685 mbpd&nbsp;(vs. 3,596 mbpd a year ago); Crude oil capacity utilization was&nbsp;94% (flat year over year).&nbsp;&nbsp;
Refining&nbsp;&amp; Marketing segment adjusted EBITDA declined to&nbsp;$1.053 billion from&nbsp;$4.373 billion a year ago due to lower market crack spreads.
Adjusted EPS for the quarter was&nbsp;$1.87,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">above the consensus of&nbsp;$0.98</a>.
As of September-end, Marathon Petroleum had&nbsp;$5.1&nbsp;billion&nbsp;of&nbsp;cash, cash equivalents,&nbsp;and&nbsp;short-term investments and&nbsp;$5 billion&nbsp;available&nbsp;on&nbsp;its bank revolving credit facility.
In the&nbsp;third quarter, the company returned around&nbsp;$3.0&nbsp;billion&nbsp;to shareholders, including&nbsp;$2.7&nbsp;billion&nbsp;in share repurchases and&nbsp;$273&nbsp;million&nbsp;in dividends. Through&nbsp;October 31, the company bought back an additional&nbsp;$0.5 billion&nbsp;of shares.
Additionally, the company&#8217;s board approved an incremental&nbsp;$5 billion&nbsp;share repurchase authorization. With the addition of this new authorization, Marathon Petroleum has&nbsp;$8.5 billion&nbsp;available under its share repurchase authorizations.&nbsp;
On&nbsp;October 30, the company increased its quarterly dividend to&nbsp;$0.91&nbsp;per share. The dividend is payable&nbsp;on December 10 to shareholders of record on&nbsp;November 20.&nbsp;&nbsp;&nbsp;
Outlook: Marathon Petroleum expects&nbsp;fourth-quarter Refining operating costs per barrel of&nbsp;$5.50 and&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">Refinery throughputs of 2,880 mbpd</a>.&nbsp;
Marathon Petroleum owns the general partner and majority limited partner interest in&nbsp;MPLX LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>), which reported&nbsp;third-quarter earnings per limited partner unit of&nbsp;$1.01, missing the consensus of&nbsp;$1.07, and revenues&nbsp;of&nbsp;$2.97 billion,&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41740434/mplx-lp-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">missing the consensus of&nbsp;$3.09 billion</a>.&nbsp;MPLX returned&nbsp;$949 million of capital to unitholders in the quarter.
Investors can gain exposure to the stock via&nbsp;iShares U.S. Oil &amp; Gas Exploration &amp; Production ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IEO#BATS">IEO</a>) and&nbsp;VanEck Oil Refiners ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRAK#NYSE">CRAK</a>).
Price Action: MPC shares are up 2.80% at $149.00 premarket at the last check Tuesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41295799/3-midstream-stocks-poised-to-benefit-as-geopolitical-tensions-rise" target="_blank" rel="noreferrer noopener">3 Midstream Stocks Poised to Benefit as Geopolitical Tensions Rise</a></li>
</ul>

Earnings

Equities

Large Cap

Guidance

Dividends

Buybacks

Movers

CRAK

iShares Dow Jones US Oil & Gas Exploration & Production Index Fund

MPLX

Marathon Petroleum Q3 Earnings: Outpaces Expectations, Powers Up Shareholder Rewards & More

WIIM

LIND

Lindblad Expeditions shares are trading higher after the company reported better-than-expected Q3 financial results.

DLTR

Dollar Tree shares are trading higher after JP Morgan maintained a Neutral rating on the stock an raised its price target from $70 to $82.

HDSN

Hudson Technologies shares are trading lower after the company reported worse-than-expected Q3 revenue results and Canaccord Genuity cut its price target on the stock from $8.75 to $8.

SPPL

Simpple Ltd shares are trading higher after the company announced its plan to regain NASDAQ compliance.

The Board of Directors approved an incremental $5 billion share repurchase authorization. With the addition of this new authorization, the company has $8.5 billion available under its share repurchase authorizations.&nbsp;

Marathon Petroleum Approved Incremental $5B Stock Buyback Authorization

Management

ADIL

Adial Pharmaceuticals Appoints Vinay Shah As Chief Financial Officer, Effective Nov. 16

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.verint.com%2F&amp;esheet=54147052&amp;newsitemid=20241105841152&amp;lan=en-US&amp;anchor=Verint%26%23174%3B&amp;index=1&amp;md5=cd382155b60eff877615bca4ef844957">Verint&#xAE;</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>), The CX Automation Company&#x2122;, today announced that a leading bank awarded Verint an $11 million contract for its AI-powered Agent Copilot Bot to assist 6,500 agents in their contact center.&#x2A;
The bank's contact center agents speak with customers for approximately 400 million minutes each year. The Verint AI-powered bot is designed to listen to these calls in the background and provide agents with real-time assistance, including coaching and guidance.
The bank conducted a pilot before awarding the contract and, based on the pilot result, the estimated annual savings from deploying the AI-powered bot is in the tens of millions of dollars.

Contracts

VRNT

Leading Bank Awards Verint $11M Contract For AI-Powered Agent Copilot Bot To Assist 6,500 Agents In Their Contact Center

BEAM

Beam Therapeutics shares are trading lower in reaction to a report indicating a patient in the company's CRISPR-based sickle cell treatment trial died.

SIMPPLE Outlines Plan To Regain Nasdaq Compliance, Including Potential Reverse Stock Split; Requests Hearing With Nasdaq To Seek Extension While Continuing Business Operations And Securing New Contracts

SI-BONE, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>), a&nbsp;Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced that the Centers for Medicare &amp; Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for the iFuse Bedrock Granite&#x2122; (Granite) system, used for pelvic fixation and sacroiliac joint fusion in conjunction with lumbar spinal fusion procedures, under the Medicare Hospital Outpatient Prospective Payment System. TPT payment status, which will be effective up to three years beginning January 1, 2025, allows patient access to new and innovative technology like Granite by providing an add-on payment to hospitals and ambulatory surgery centers supporting it.
As part of the TPT determination, CMS confirmed that a customary deduction from the add-on payment, known as a device offset, will not be applied to lumbar spinal fusion procedures involving pelvic fixation with Granite. This decision recognizes that Granite costs are not currently included in the existing facility payment amount for the procedures using this technology.

SIBN

SI-BONE Receives Transitional Pass-Through Payment Status For iFuse Bedrock Granite System, Used For Pelvic Fixation And Sacroiliac Joint Fusion In Conjunction With Lumbar Spinal Fusion Procedures, Under The Medicare Hospital Outpatient Prospective Payment System

Simpple Ltd, A Leading Technology Provider Announced Its Plan To Regain NASDAQ Compliance

BLDP

Ballard Power Systems Expects Revenue In 2024 To Be Weighted Towards Q4

The New York State Common Retirement Fund has significantly reduced its stake in Vistra Corp., according to a recent filing with the Securities &amp; Exchange Commission (SEC). This move was executed during the third quarter.
What Happened: The fund divested 43,440 shares, marking a 21.6% reduction in its Vistra Corp. holdings. Following this transaction, the fund retains 157,565 shares of the company&#8217;s stock, valued at $18,678,000 as per the latest SEC filing. This adjustment is part of the fund&#8217;s broader portfolio management strategy.
The change in the portfolio comes at a time when Vistra Corp&#8217;s year-to-date (YTD) returns have crossed 200%. As per Benzinga Pro, Vistra Corp was trading 0.24% higher on Tuesday during pre-market than its previous day close at $115.74.
See Also: <a href="https://www.benzinga.com/news/24/11/41705158/cathie-wood-says-trumps-ideas-on-eliminating-income-tax-and-imposing-tariffs-brings-back-vibes-of-ea?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Cathie Wood Says Trump&#8217;s Ideas On Eliminating Income Tax And Imposing Tariffs Brings Back Vibes Of &#8216;Early</a>
Why It Matters: Texas-based Vistra Corp. <a href="https://www.benzinga.com/insights/news/24/11/41715992/evaluating-vistra-against-peers-in-independent-power-and-renewable-electricity-producers-industry">stands as a major player</a> in the Independent Power and Renewable Electricity Producers industry. It is one of the largest power producers and retail energy providers in the U.S., especially after acquiring Energy Harbor in 2024. This acquisition expanded Vistra&#8217;s portfolio to include 41 gigawatts of nuclear, coal, natural gas, and solar power generation, alongside one of the world&#8217;s largest utility-scale battery projects.
Vistra&#8217;s retail electricity business serves approximately 5 million customers across 20 states, covering nearly a third of Texas&#8217;s electricity consumers. The company emerged as an independent entity in 2016 after the bankruptcy of Energy Future Holdings and further expanded by acquiring Dynegy in 2018.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41705665/palantir-technologies-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Palantir Technologies Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Top Analysts</a></li>
</ul>
Image via Midjourney
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Markets

New York State Common Retirement Fund Pares Vistra Corp Stake After Shares Rally Over 200% This Year

Artelo Biosciences, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that ART26.12, the Company's lead clinical FABP inhibitor, has been accepted into the NIH Helping to End Addiction Long Term (HEAL) Initiative's Preclinical Screening Platform for Pain (PSPP).
The HEAL Initiative is an NIH-wide effort to accelerate scientific solutions to the overdose epidemic, including opioid and stimulant use disorders, and the crisis of pain. Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management. For more information, visit: <a href="https://www.globenewswire.com/Tracker?data=V0OIqyLfFcY5W7pjPpAuOgSxpFF0XIvawVscW4wbdwg7V_FhA3Ltt3AEUAniLYFzGCWmQxbGtaOlCTeoy9z_gw==">https://heal.nih.gov</a>.
The PSPP program, part of the NIH HEAL Initiative, evaluates non-opioid assets in a battery of established preclinical pain models. The PSPP program accepts small molecules, biologics,&nbsp;devices,&nbsp;or natural products for evaluation, from researchers in academia and industry worldwide. For more information, visit: <a href="https://www.globenewswire.com/Tracker?data=V0OIqyLfFcY5W7pjPpAuOlGjlyIIOqxGCXGg7oAt6Z8k_ceVEneHLI1vwxQ_6cUhkiltyTw8QQT1pV5d70643HL2HPZdhRFfxJaV9YNhfRmH9nfw_RF6CKHtAfA4IrI-OAUc2GDix2f8AgJTeD-gGsZnWraYf9DQLl_KK0KyPERmmZ2qiTanbmibjkbPuCBhaatGJ8TqR2NK9mw7c9BFBPeEx1kzbGwZK3J_7R1YWB0=">https://heal.nih.gov/research/preclinical-translational/screening-platform</a>.
The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

ARTL

Artelo Biosciences Announces Acceptance Of ART26.12 Into The National Institutes Of Health's Helping To End Addiction Long Term Initiative's Preclinical Screening Platform For Pain

MPLX shares are trading higher. The company reported Q3 financial results.

TCMD

Tactile Systems Tech shares are trading lower after BTIG downgraded the stock from Buy to Neutral.

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on GH Research (GHRS – Research Report) today and set a price target of $40.00. Pa...

Buy Rating Affirmed on GH Research Amid Anticipated Phase 2 Advances and Strong Market Potential

The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a Portfolio of the 4 largest such companies.

Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August

TD Cowen analyst Ritu Baral has maintained their bullish stance on GHRS stock, giving a Buy rating yesterday. I'm sorry, but I cannot provide the r...

Understanding Incomplete Data: A Call for Comprehensive Analyst Reports

GH Research (GHRS) has released an update. GH Research PLC, an Ireland-based company, has announced its participation in the upcoming H.C. Wainwrig...

GH Research to Engage at Global Investment Conference

While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are having growing pains.

Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th

The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come.

Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week

GH Research (GHRS) has released an update. GH Research PLC has announced their participation in the upcoming Cantor Global Healthcare Conference, s...

GH Research Engages Investors at Healthcare Conference

GH Research (GHRS) has released an update. GH Research is advancing its clinical trials on a new, inhalable synthetic formulation of the psychedeli...

GH Research Advances Psychedelic TRD Treatment Trials

Bright Minds rally ends as psychedelic stocks extend volatility

FDA is said to see "path forward" for ecstasy-based drug

ATAI

ATNF

CMND

CMPS

CYBN

DRUG

ENVB

GHRS

MNMD

RVVTF

Press Releases

GH Research Reports Third Quarter Financial Results and Provides Business Updates

Legal

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates

Health Care

GH Research Announces Appointment of Dr. Velichka "Villy" Valcheva to Chief Executive Officer

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

Comments

GH Research

GH Research (GHRS) Opzioni

GH Research (NASDAQ:GHRS) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO